Alkermes to Release Q2 Financial Results on July 29, 2025

Alkermes will report its Q2 financial results on July 29, 2025. The company will host a conference call and webcast presentation at 8:00 a.m. ET to discuss the results. The webcast and slides will be available on Alkermes' website, and the conference call can be accessed by dialing +1 877 407 2988 for US callers or +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of the event.

Alkermes plc (Nasdaq: ALKS) will release its second-quarter financial results on Tuesday, July 29, 2025. The company will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) to discuss the results. The webcast and accompanying slides will be available on Alkermes' website, and the conference call can be accessed by dialing +1 877 407 2988 for U.S. callers or +1 201 389 0923 for international callers. A replay of the webcast will be available approximately two hours after the completion of the event [1].

Alkermes is a global biopharmaceutical company focused on developing innovative medicines in the field of neuroscience. The company's portfolio includes proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder, as well as a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia [2].

Analysts have shown interest in Alkermes, with several firms initiating coverage with buy ratings. For instance, Goldman Sachs initiated coverage on Alkermes with a Buy rating and a 12-month price target of $43, citing the company's established commercial portfolio and pipeline of neuropsych assets [3]. TD Cowen also initiated a Buy rating on Alkermes based on promising narcolepsy treatment developments [4].

Investors are encouraged to tune in to the conference call and webcast to gain insights into Alkermes' financial performance and future prospects. The event will provide an opportunity to hear from management and analysts about the company's financial health, strategic initiatives, and plans for the remainder of the year.

References:
[1] Alkermes to Report Second-Quarter Financial Results on July 29, 2025. (2025). PRNewswire. Retrieved from https://www.prnewswire.com/news-releases/alkermes-to-report-second-quarter-financial-results-on-july-29-2025-302505916.html
[2] Alkermes to Report Second-Quarter Financial Results on July 29, 2025. (2025). PRNewswire. Retrieved from https://www.prnewswire.co.uk/news-releases/alkermes-to-report-second-quarter-financial-results-on-july-29-2025-302505926.html
[3] Tuesday's biggest calls on Wall Street. (2025). CNBC. Retrieved from https://www.cnbc.com/2025/07/15/tuesday-stocks-to-watch-from-analyst-calls-like-nvidia.html
[4] Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS) and Centessa Pharmaceuticals (CNTA). (2025). CNN. Retrieved from https://www.cnn.com/markets/stocks/ALKS